BLTE
Belite Bio, Inc American Depositary Shares
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
Belite Bio (BLTE) Stock: Buy, Sell, or Hold?
$169.96
+14.02 (+8.99%)
▲
5d:
+18.7%
30d:
+11.29%
90d:
+4.4%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (51%)
Quality Score
45/100
Position
EXTENDED
30-Day Fair Range
$147.25 – $158.21
Position: EXTENDED
Forward P/E & Valuation
75.2x
CHEAP
vs 141.5x historical avg
Wall Street Target
$227.44
+33.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$141.00 / $170.89
Trend: Sideways
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: BLTE shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When BLTE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$79.17
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$49.16
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BLTE is currently trading at $169.96, which is considered extended relative to its 30-day fair value range of $147.25 to $158.21. From a valuation perspective, the stock is trading at a discount (Forward PE: 75.2) compared to its historical average (141.5). Remarkably, the market is currently pricing in an annual earnings decline of 19.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BLTE is showing sideways momentum. The price is approaching resistance at $170.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.0% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $227.44 (+33.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BLTE is showing sideways momentum. The price is approaching resistance at $170.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.0% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $227.44 (+33.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$147.25 -
$158.21
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.0%
Trading Range & Key Levels
30-Day Trading Range
$147.25 -
$158.21
Current vs Trading Range
EXTENDED
Support Level
$141.00
Resistance Level
$170.89
Current Trend
Sideways
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range (+7.4% above its trading range)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.0%)
- BULLISH: Trading 33.8% below Wall St target ($227.44)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
75.20
Wall Street Target
$227.44
(+33.8%)
Valuation Discount vs History
-19.0% cheaper
PE vs Historical
75.2 vs 141.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-19.0%
(market-implied from PE analysis)
1-Year Target
$152.96
(-10%)
2-Year Target
$137.67
(-19%)
3-Year Target
$123.90
(-27%)
3-Yr Target (if PE normalizes)
(PE: 75→142)
$233.13
(+37%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 75.2 to 141.5
Stabilization Target:
$319.79
(+88.2%)
PE Expansion Potential:
+88.2%
Share BLTE Analysis
Share this live BLTE analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 13, 2026 4:57 AM ET
Data refreshes hourly during market hours. Next update: 5:57 AM
Data refreshes hourly during market hours. Next update: 5:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BLTE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 31 SELL |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
18 analysts |
$139 | 41 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
18 analysts |
$122 | 44 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive BLTE Research Pages
